News
AstraZeneca on Wednesday said that its experimental therapy anselamimab did not meet the main goal of a late-stage study for ...
AstraZeneca said on Monday its experimental drug baxdrostat significantly lowered blood pressure in a late-stage trial of ...
AstraZeneca's experimental drug baxdrostat has been successful in lowering high blood pressure in a late-stage study of ...
19h
Zacks.com on MSNAstraZeneca Meets All Key Goals in Phase III Hypertension StudyAZN hits all endpoints in phase III study for baxdrostat, a first-in-class treatment targeting hard-to-manage hypertension.
Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...
Positive high-level results in trials of its baxdrostat drug to treat hypertension provided AstraZeneca shares with a ...
Explore more
AstraZeneca (LSE:AZN) recently experienced a weekly price move of 2% amid announcements that could have supported its ...
AstraZeneca's baxdrostat demonstrated significant blood pressure reduction in a late-stage trial for treatment-resistant ...
AstraZeneca’s $1.3 billion bet on CinCor Pharma and its mid-phase hypertension drug baxdrostat seems to have paid off based ...
The drug came to AstraZeneca through its acquisition of CinCor Pharma in 2023, with the hopes of beefing up its ...
22h
Clinical Trials Arena on MSNAstraZeneca’s Phase III trial of baxdrostat shows mean SBP reductionAstraZeneca has reported positive outcomes from the BaxHTN Phase III trial of the highly selective ASI, baxdrostat.
AstraZeneca’s Phase III BaxHTN trial shows that baxdrostat significantly lowers systolic blood pressure in resistant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results